# Safety and Tolerability of Rituximab in Neuromyelitis Optica

> **NCT00501748** · PHASE1 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 20 (actual)

## Conditions studied

- Neuromyelitis Optica

## Interventions

- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT00501748
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2011-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00501748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00501748, "Safety and Tolerability of Rituximab in Neuromyelitis Optica". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00501748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*